 | • レポートコード：MRC2303K049 • 出版社/出版日：Mordor Intelligence / 2023年2月 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：バイオ |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の調査レポートでは、世界の糖鎖生物学市場規模が、予測期間中、CAGR 14.6％で増大すると予測されています。本レポートでは、糖鎖生物学の世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品別（酵素、器具、キット・試薬）分析、用途別（診断、腫瘍、免疫、その他）分析、エンドユーザー別（製薬・バイオテクノロジー企業、受薬研究機関、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などについて調査・分析などの項目を掲載しています。並び、こちらのレポートには、Agilent Technologies、Bruker Corporation、Danaher Corporation、Merck KGaA、New England Biolabs、ProZyme、Shimadzu Corporation、Takara Bio、Thermo Fisher Scientific、Waters Corporationなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の糖鎖生物学市場規模：製品別 - 酵素の市場規模 - 器具の市場規模 - キット・試薬の市場規模 ・世界の糖鎖生物学市場規模：用途別 - 診断における市場規模 - 腫瘍における市場規模 - 免疫における市場規模 - その他用途における市場規模 ・世界の糖鎖生物学市場規模：エンドユーザー別 - 製薬・バイオテクノロジー企業における市場規模 - 受薬研究機関における市場規模 - そのエンドユーザーにおける市場規模 ・世界の糖鎖生物学市場規模：地域別 - 北米の糖鎖生物学市場規模 アメリカの糖鎖生物学市場規模 カナダの糖鎖生物学市場規模 メキシコの糖鎖生物学市場規模 … - ヨーロッパの糖鎖生物学市場規模 ドイツの糖鎖生物学市場規模 イギリスの糖鎖生物学市場規模 フランスの糖鎖生物学市場規模 … - アジア太平洋の糖鎖生物学市場規模 中国の糖鎖生物学市場規模 日本の糖鎖生物学市場規模 インドの糖鎖生物学市場規模 … - 南米/中東の糖鎖生物学市場規模 南アフリカの糖鎖生物学市場規模 ブラジルの糖鎖生物学市場規模 アルゼンチンの糖鎖生物学市場規模 … ・競争状況 ・市場機会・将来動向 |
The glycobiology market is poised to register a CAGR of 14.6% over the forecast period.
Several vaccine development efforts related to COVID-19 primarily focused on the coronavirus transmembrane spike (S) glycoprotein, which extends from the viral surface and mediates host cell entry. A critical step in this crosstalk between the virus and the host cell is the binding of S-glycoprotein to the ACE2 receptor on the surface of human cells. Both S-glycoprotein and ACE2 receptors are known to be extensively glycosylated, i.e., they contain covalently linked complex oligosaccharides called glycans. This makes a promising research path on glycans during the pandemic. Many research studies proved that glycans are crucial in COVID-19 infection. A March 2021 research study by researchers at RIKEN Center for Computational Science (R-CCS) found that glycans sugar molecules play an essential role in the structural changes that occur when the virus causes COVID-19 to invade human cells.
According to a study published in the Journal of Molecular Biology in June 2021, glycan-binding proteins are involved in both human defense and the ability of viruses to infect. Drugs that should be considered for COVID-19 prevention and treatment include glycan antigens, anti-glycan antibodies, glycan-binding proteins, lectin inhibitors, polysaccharides, glycosidase inhibitors, and glycosides. Thus, the above-mentioned factors state that the global glycobiology market was significantly impacted by the COVID-19 pandemic. However, the market is currently gaining its pre-pandemic nature and is expected to witness healthy growth over the forecast period.
The major factor responsible for the growth of the glycobiology market is the increasing research and development activities about glycomes and emerging technology for analyzing glycans and proteomes. Glycans, generally present on the cell surface, play a crucial role in the body system. They are responsible for many hereditary diseases and have a vital role in cancer development. In December 2021, Griffith University’s Institute for Glycomics of Australia received a grant of USD 1.80 million from the Australian Cancer Research Foundation (ACRF) to establish the ACRF International Centre for Cancer Glycomics. In August 2022, GlycoNet, a pan-Canadian network of Centers of Excellence centered at UAlberta, received a USD 10.68 million investment from the Canadian Foundation for Innovation’s Major Science Initiative Fund to continue its mission of researching glycomics for the benefit of human health.
Thus, owing to the above-mentioned factors, the market studied is believed to witness strong growth over the forecast period.
Glycobiology Market Trends
Drug Discovery and Development is Expected to be the Largest Growing Segment
As the burden of chronic diseases increases, the need to develop new drugs is also increasing. Glycans play a key role in biological processes, such as cell-cell interaction, and thus have immense importance in drug development. Therefore, glycan chains are modified to synthesize drugs. For instance, hyaluronan, a naturally occurring disaccharide unit of glycosaminoglycan, has wide applications in medicine. It is used in post-surgical wounds and is essential in osteoarthritis treatment.
According to a study published in the International Journal of Nanomedicine in July 2021, glycan nanostructures are thought to be potential targets for molecular diagnosis, antiviral therapeutics, and vaccine development. The development of vaccines, drug delivery systems, and biomolecular therapeutics for viruses and infectious diseases can be enabled by studying glycans at the nanoscale. Glycan-based self-adjuvanted vaccines can be created to improve immunogenicity and vaccine response using glycoprotein expression systems and genetic engineering tools. Thus, glycobiology plays an essential role in the development of vaccines, thereby boosting the growth of the segment. In February 2022, Mizutani Foundation for Glycoscience received 119 research grant applications from 28 countries. After careful evaluation of scientific and social merit, potentiality, and feasibility, the Foundation decided to award grants of approximately USD 0.51 million to 14 projects. Thus, grants and approvals are expected to boost research and development in glycobiology, thereby boosting the growth of the segment.
North America is Expected to Dominate the Market Over the Forecast Period
The increasing research and development activities and government funding programs, along with the growing burden of chronic diseases in the United States, are expected to create more opportunities for the North America region. In September 2022, Cold Spring Harbor Laboratory Press (CSHL Press), a publisher of scientific books, journals, and electronic media established a new program to provide access to the field of glycobiology, which is developing rapidly across the United States. InterVenn Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, is involved in supporting the grant for CSHL Press. This indicates the increasing focus on glycobiology which is expected to fuel the market growth in coming years across the United States.
In March 2022, Vector Laboratories, the pioneer of innovative proteomic and glycobiology solutions, opened its new facility in Newark, California. These immunofluorescence (IF) kits enable the profiling and characterization of complex glycans in biological systems and are completely integrated for the detection of glycan expression in tissue sections. As more researchers express interest in studying glycobiology due to the potential impact it may have on important areas of illness research like oncology, glycan research is continuing to gain popularity. Hence, owing to the above-mentioned factors, the market studied is expected to witness strong growth over the forecast period.
Glycobiology Market Competitor Analysis
The glycobiology market is moderately competitive, with the presence of a considerable number of companies that significantly contribute to the market growth. New product launches, mergers and acquisitions, partnerships, and collaborations are the key strategies adopted by these companies for sustainable growth. Some key companies in the market include Agilent Technologies, Waters Corporation, Shimadzu Corporation, Merck KGaA, and New England Biolabs, among others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Government and Private Funding for Glycomics and Proteomics Research
4.2.2 Growing R&D Expenditures by Pharmaceutical and Biotechnology Companies
4.3 Market Restraints
4.3.1 High Product Cost
4.3.2 Low Availability of Skilled Professionals
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size – Value in USD million)
5.1 By Product
5.1.1 Enzymes
5.1.2 Instruments
5.1.3 Kits and Reagents
5.2 By Application
5.2.1 Diagnostics
5.2.2 Drug Discovery and Development
5.2.3 Oncology
5.2.4 Immunology
5.2.5 Other Applications
5.3 By End User
5.3.1 Pharmaceutical and Biotechnology Companies
5.3.2 Contract Research Organizations
5.3.3 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Agilent Technologies
6.1.2 Bruker Corporation
6.1.3 Danaher Corporation
6.1.4 Merck KGaA
6.1.5 New England Biolabs
6.1.6 ProZyme
6.1.7 Shimadzu Corporation
6.1.8 Takara Bio
6.1.9 Thermo Fisher Scientific
6.1.10 Waters Corporation
7 MARKET OPPORTUNITIES AND FUTURE TRENDS